{
    "name": "lincomycin",
    "comment": "Rx",
    "other_names": [
        "Lincocin"
    ],
    "classes": [
        "Antibiotics",
        "Lincosamide"
    ],
    "source": "https://reference.medscape.com/drug/lincocin-lincomycin-342555",
    "pregnancy": {
        "common": [
            "There are no adequate and well-controlled studies in pregnant women; sterile Solution contains benzyl alcohol as a preservative; benzyl alcohol can cross placenta; should be used during pregnancy only if clearly needed; experience with obstetrical patients receiving drug revealed no ill effects related to pregnancy"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "No evidence of teratogenicity when drug administered in diet or via oral gavage to pregnant Sprague Dawley rats during period of major organogenesis at doses up to 5000 mg/kg and 100 mg/kg (approximately 6 times and 0.12 times the maximum recommended human dose [MRHD], respectively, based on body surface area comparison)",
                    "Reproduction studies performed in rats administered drug for 2 weeks prior to mating, throughout pregnancy and lactation, revealed no adverse effects on survival of offspring from birth to weaning at doses up to 1000 mg/kg (1.2 times the MRHD based on body surface area comparison) up to 2 generations"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Drug has been reported to appear in human milk in concentrations of 0.5 to 2.4 mcg/mL; because of potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing, or to discontinue drug, taking into account importance of drug to mother"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Pseudomembranous colitis may range from severe to mild to life-threatening",
                "Reserve use for serious infections only",
                "Do not use this drug in patients with nonbacterial infections",
                "Clostridioides difficile (C. difficile)-associated diarrhea (CDAD) should be considered in patients who present with diarrhea following antibiotic use; C difficile produces toxins A and B, which contribute to the development of CDAD",
                "Hypertoxin-producing strains of C difficile caused increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy",
                "If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C difficile may need to be discontinued",
                "Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation should be instituted as clinically indicated"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to lincomycin or clindamycin"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Not for gram-positive bacteria",
                "Use caution in patients with history of GI disease (colitis), asthma or allergies",
                "Discontinue if persistent diarrhea occurs",
                "Clostridioides difficile associated diarrhea (CDAD) reported with use of nearly all antibacterial agents, including this drug, and may range in severity from mild diarrhea to fatal colitis; careful medical history is necessary since CDAD has been reported to occur over two months after administration of antibacterial agents",
                "Review of experience to date suggests that a subgroup of older patients with associated severe illness may tolerate diarrhea less well; when drug is indicated in these patients, they should be carefully monitored for change in bowel frequency",
                "Prescribe with caution in individuals with a history of gastrointestinal disease, particularly colitis",
                "Parenteral formulation contains benzyl alcohol as a preservative; benzyl alcohol has been associated with serious adverse events, including “gasping syndrome”, and death in pediatric patients; although normal therapeutic doses of this product ordinarily deliver amounts of benzyl alcohol substantially lower than those reported in association with “gasping syndrome”, the minimum amount of benzyl alcohol at which toxicity may occur is not known; the risk of benzyl alcohol toxicity depends on quantity administered and liver and kidneys’ capacity to detoxify the chemical; premature and low-birth-weight infants may be more likely to develop toxicity",
                "Severe hypersensitivity reactions, including anaphylactic reactions and severe cutaneous adverse reactions (SCAR) such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP), and erythema multiforme (EM) reported; if anaphylactic reaction or severe skin reaction occurs, discontinue drug and initiate appropriate therapy",
                "Certain infections may require incision and drainage or other indicated surgical procedures in addition to antibacterial therapy",
                "Must be diluted prior to intravenous infusion; for intravenous infusion, infuse over at least 60 minutes as directed; not for administration as an intravenous bolus; severe cardiopulmonary reactions have occurred at greater than the recommended concentration and rate",
                "Prescribing drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria",
                "Therapy may result in overgrowth of nonsusceptible organisms—particularly yeasts; should superinfections occur, appropriate measures should be taken as indicated by clinical situation; when patients with pre-existing monilial infections require therapy with lincomycin, concomitant antimonilial treatment should be given; when patients with pre-existing Candida infections require therapy, concomitant antifungal treatment should be given",
                "Serum half-life of lincomycin may be prolonged in patients with severe impairment of renal function compared to patients with normal renal function; in patients with abnormal hepatic function, serum half-life may be twofold longer than in patients with normal hepatic function; patients with severe renal impairment and/or hepatic impairment should be dosed with caution and serum lincomycin concentrations monitored during high-dose therapy",
                "Although lincomycin appears to diffuse into cerebrospinal fluid, concentrations of lincomycin in the CSF may be inadequate for treatment of meningitis"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "atracurium",
            "description": {
                "common": "lincomycin increases effects of atracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "lincomycin, cholera vaccine. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cisatracurium",
            "description": {
                "common": "lincomycin increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "microbiota oral",
            "description": {
                "common": "lincomycin decreases effects of microbiota oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Microbiota oral contains bacterial spores. Antibacterial agents may decrease efficacy if coadministered. Complete antibiotic regimens 2-4 days before initiating microbiota oral. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "onabotulinumtoxinA",
            "description": {
                "common": "lincomycin increases effects of onabotulinumtoxinA by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pancuronium",
            "description": {
                "common": "lincomycin increases effects of pancuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rapacuronium",
            "description": {
                "common": "lincomycin increases effects of rapacuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rocuronium",
            "description": {
                "common": "lincomycin increases effects of rocuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "succinylcholine",
            "description": {
                "common": "lincomycin increases effects of succinylcholine by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vecuronium",
            "description": {
                "common": "lincomycin increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rimabotulinumtoxinB",
            "description": {
                "common": "lincomycin, rimabotulinumtoxinB.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Aminoglycosides may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium picosulfate/magnesium oxide/anhydrous citric acid",
            "description": {
                "common": "lincomycin decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "Tenesmus",
            "percent": null
        },
        {
            "name": "Glossitis",
            "percent": null
        },
        {
            "name": "Stomatitis",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Angioedema",
            "percent": null
        },
        {
            "name": "Serum sickness and anaphylactic or anaphylactoid reactions",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "Vaginitis",
            "percent": null
        },
        {
            "name": "Exfoliative",
            "percent": null
        },
        {
            "name": "vesiculobullous dermatitis",
            "percent": null
        },
        {
            "name": "Erythema multiforme",
            "percent": null
        },
        {
            "name": "Thrombophlebitis",
            "percent": null
        },
        {
            "name": "Erythema",
            "percent": null
        },
        {
            "name": "Pain",
            "percent": null
        },
        {
            "name": "Swelling",
            "percent": null
        },
        {
            "name": "Transient increases in serum bilirubin",
            "percent": null
        },
        {
            "name": "alkaline phosphatase",
            "percent": null
        },
        {
            "name": "AST",
            "percent": null
        },
        {
            "name": "SGOT",
            "percent": null
        },
        {
            "name": "concentrations",
            "percent": null
        },
        {
            "name": "Jaundice",
            "percent": null
        },
        {
            "name": "Transient leukopenia",
            "percent": null
        },
        {
            "name": "neutropenia",
            "percent": null
        },
        {
            "name": "eosinophilia",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Agranulocytosis",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Myalgia",
            "percent": null
        },
        {
            "name": "Tinnitus",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Vertigo",
            "percent": null
        },
        {
            "name": "Anal pruritus",
            "percent": null
        },
        {
            "name": "pseudomembranous colitis",
            "percent": null
        },
        {
            "name": "Clostridium difficile colitis",
            "percent": null
        },
        {
            "name": "pancytopenia",
            "percent": null
        },
        {
            "name": "aplastic anemia",
            "percent": null
        },
        {
            "name": "thrombocytopenic purpura",
            "percent": null
        },
        {
            "name": "liver function test abnormal",
            "percent": null
        },
        {
            "name": "transaminases increased",
            "percent": null
        },
        {
            "name": "renal impairment",
            "percent": null
        },
        {
            "name": "oliguria",
            "percent": null
        },
        {
            "name": "proteinuria",
            "percent": null
        },
        {
            "name": "azotemia",
            "percent": null
        },
        {
            "name": "cardio",
            "percent": null
        },
        {
            "name": "respiratory arrest",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Toxic epidermal necrolysis",
            "percent": null
        },
        {
            "name": "Stevens",
            "percent": null
        },
        {
            "name": "Johnson syndrome",
            "percent": null
        },
        {
            "name": "acute generalized exanthematous pustulosis",
            "percent": null
        },
        {
            "name": "dermatitis bullous",
            "percent": null
        },
        {
            "name": "dermatitis exfoliative",
            "percent": null
        },
        {
            "name": "erythema multiforme",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "pruritus may occur",
            "percent": null
        }
    ]
}